Large mediastinal mass (LMM) in children with Hodgkin's disease (HD) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Large mediastinal mass (LMM) in children with Hodgkin's disease (HD) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 15:A1334 1996. Unique Identifier : AIDSLINE ICDB/97636334
Graziano J; Leonidas J; Lanzkowsky P; Karayalcin G; Albert Einstein College of Medicine at Long Island Jewish Medical; Center, Schneider Children's Hospital, New Hyde Park, NY 11040

Abstract: We reviewed the records of all patients diagnosed and treated for HD with LMM at Schneider Children's Hospital between 1984-1994. LMM was defined as the maximum transverse width of the mass on PA chest film exceeding 33% of the width of the thoracic cage at its maximum. A total of 27 patients were studied (12 female and 15 male). The age range was 12 to 21 years (mean 15.8 years). Histologic subtypes were 26 NC, 1 MC. Stages (S) were as follows: IIA (8); IIB (7); IIIA (2); IIIB (6); IV (4). All patients received combined modality therapy (CMT). Twenty-five of 27 patients remain in continuous complete remission for 10 to 143 months from completion of therapy (mean 66 months). One patient (SIIIB), relapsed outside of the radiation field 19 months after complete remission (CR) and was then treated with ABMT; he remains in CR for 39 months. One patient (SIV) had progressive disease and despite ABMT died 60 months from the diagnosis. The 5-year disease free survival (DFS) and event-free survival (EFS) were 95.8% and 89.6%, respectively, for all patients. These observations suggest that the use of initial CMT may yield DFS and EFS for patients with LMM similar to those of patients with small or no mediastinal disease.
Keywords: Adolescence Adult Child Combined Modality Therapy Disease-Free Survival Female Human Male Mediastinal Neoplasms/*PATHOLOGY/THERAPY Recurrence Remission Induction ABSTRACTKWDadolescenceadultchildcombinedmodalitytherapydisease-freesurvivalfemalehumanmalemediastinalneoplasms/KWDpathology/therapyrecurrenceremissioninductionabstract
970330
M9731527

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .